Cargando…

Segment 2/3 Hypertrophy is Greater When Right Portal Vein Embolisation is Extended to Segment 4 in Patients with Colorectal Liver Metastases: A Retrospective Cohort Study

BACKGROUND: In patients with colorectal cancer liver metastases (CRLM), right portal vein embolisation (RPVE) is used to increase the volume of the future remnant liver (FRL) before major hepatic resection. It is not established whether embolisation of segment 4 in addition RPVE (RPVE + 4) induces g...

Descripción completa

Detalles Bibliográficos
Autores principales: Hammond, Christopher J., Ali, Saadat, Haq, Hafizul, Luo, Lorna, Wyatt, Judith I., Toogood, Giles J., Lodge, J. Peter A., Patel, Jai V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394476/
https://www.ncbi.nlm.nih.gov/pubmed/30656390
http://dx.doi.org/10.1007/s00270-018-02159-5
_version_ 1783398903207428096
author Hammond, Christopher J.
Ali, Saadat
Haq, Hafizul
Luo, Lorna
Wyatt, Judith I.
Toogood, Giles J.
Lodge, J. Peter A.
Patel, Jai V.
author_facet Hammond, Christopher J.
Ali, Saadat
Haq, Hafizul
Luo, Lorna
Wyatt, Judith I.
Toogood, Giles J.
Lodge, J. Peter A.
Patel, Jai V.
author_sort Hammond, Christopher J.
collection PubMed
description BACKGROUND: In patients with colorectal cancer liver metastases (CRLM), right portal vein embolisation (RPVE) is used to increase the volume of the future remnant liver (FRL) before major hepatic resection. It is not established whether embolisation of segment 4 in addition RPVE (RPVE + 4) induces greater hypertrophy of the FRL. Limitations of prior studies include heterogenous populations and use of hypertrophy metrics sensitive to baseline variables. METHODS: From 2010 to 2015, consecutive patients undergoing RPVE or RPVE + 4 for CRLM, who had not undergone prior major hepatic resection and in whom imaging was available, were included in a retrospective study. Data were extracted from hospital electronic records. Volumetric assessments of segments 2–3 were made on cross-sectional imaging before and after embolisation and corrected for standardised liver volume. RESULTS: Ninety-nine patients underwent PVE, and 60 met the inclusion criteria. Thirty-eight patients underwent RPVE, and 22 underwent RPVE + 4. Forty-five patients had undergone median 6 cycles of prior chemotherapy. Eighteen patients had FRL metastases at PVE, and 16 had undergone subsegmental metastasectomy in the FRL. Assessments of the degree of hypertrophy (DH) of segments 2/3 were made at median 35 (interquartile range 30–49) days after PVE. RPVE + 4 resulted in a significantly greater increase in DH than RPVE (7.7 ± 1.8% vs 11.3 ± 2.6%, p = 0.011). No confounding association between baseline variables and the decision to undertake RPVE or RPVE + 4 was identified. Median survival was 2.4 years and was not influenced by segment 4 embolisation. CONCLUSION: RPVE + 4 results in greater DH of segments 2/3 than RPVE in people with CLRM.
format Online
Article
Text
id pubmed-6394476
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-63944762019-03-15 Segment 2/3 Hypertrophy is Greater When Right Portal Vein Embolisation is Extended to Segment 4 in Patients with Colorectal Liver Metastases: A Retrospective Cohort Study Hammond, Christopher J. Ali, Saadat Haq, Hafizul Luo, Lorna Wyatt, Judith I. Toogood, Giles J. Lodge, J. Peter A. Patel, Jai V. Cardiovasc Intervent Radiol Clinical Investigation BACKGROUND: In patients with colorectal cancer liver metastases (CRLM), right portal vein embolisation (RPVE) is used to increase the volume of the future remnant liver (FRL) before major hepatic resection. It is not established whether embolisation of segment 4 in addition RPVE (RPVE + 4) induces greater hypertrophy of the FRL. Limitations of prior studies include heterogenous populations and use of hypertrophy metrics sensitive to baseline variables. METHODS: From 2010 to 2015, consecutive patients undergoing RPVE or RPVE + 4 for CRLM, who had not undergone prior major hepatic resection and in whom imaging was available, were included in a retrospective study. Data were extracted from hospital electronic records. Volumetric assessments of segments 2–3 were made on cross-sectional imaging before and after embolisation and corrected for standardised liver volume. RESULTS: Ninety-nine patients underwent PVE, and 60 met the inclusion criteria. Thirty-eight patients underwent RPVE, and 22 underwent RPVE + 4. Forty-five patients had undergone median 6 cycles of prior chemotherapy. Eighteen patients had FRL metastases at PVE, and 16 had undergone subsegmental metastasectomy in the FRL. Assessments of the degree of hypertrophy (DH) of segments 2/3 were made at median 35 (interquartile range 30–49) days after PVE. RPVE + 4 resulted in a significantly greater increase in DH than RPVE (7.7 ± 1.8% vs 11.3 ± 2.6%, p = 0.011). No confounding association between baseline variables and the decision to undertake RPVE or RPVE + 4 was identified. Median survival was 2.4 years and was not influenced by segment 4 embolisation. CONCLUSION: RPVE + 4 results in greater DH of segments 2/3 than RPVE in people with CLRM. Springer US 2019-01-17 2019 /pmc/articles/PMC6394476/ /pubmed/30656390 http://dx.doi.org/10.1007/s00270-018-02159-5 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Clinical Investigation
Hammond, Christopher J.
Ali, Saadat
Haq, Hafizul
Luo, Lorna
Wyatt, Judith I.
Toogood, Giles J.
Lodge, J. Peter A.
Patel, Jai V.
Segment 2/3 Hypertrophy is Greater When Right Portal Vein Embolisation is Extended to Segment 4 in Patients with Colorectal Liver Metastases: A Retrospective Cohort Study
title Segment 2/3 Hypertrophy is Greater When Right Portal Vein Embolisation is Extended to Segment 4 in Patients with Colorectal Liver Metastases: A Retrospective Cohort Study
title_full Segment 2/3 Hypertrophy is Greater When Right Portal Vein Embolisation is Extended to Segment 4 in Patients with Colorectal Liver Metastases: A Retrospective Cohort Study
title_fullStr Segment 2/3 Hypertrophy is Greater When Right Portal Vein Embolisation is Extended to Segment 4 in Patients with Colorectal Liver Metastases: A Retrospective Cohort Study
title_full_unstemmed Segment 2/3 Hypertrophy is Greater When Right Portal Vein Embolisation is Extended to Segment 4 in Patients with Colorectal Liver Metastases: A Retrospective Cohort Study
title_short Segment 2/3 Hypertrophy is Greater When Right Portal Vein Embolisation is Extended to Segment 4 in Patients with Colorectal Liver Metastases: A Retrospective Cohort Study
title_sort segment 2/3 hypertrophy is greater when right portal vein embolisation is extended to segment 4 in patients with colorectal liver metastases: a retrospective cohort study
topic Clinical Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394476/
https://www.ncbi.nlm.nih.gov/pubmed/30656390
http://dx.doi.org/10.1007/s00270-018-02159-5
work_keys_str_mv AT hammondchristopherj segment23hypertrophyisgreaterwhenrightportalveinembolisationisextendedtosegment4inpatientswithcolorectallivermetastasesaretrospectivecohortstudy
AT alisaadat segment23hypertrophyisgreaterwhenrightportalveinembolisationisextendedtosegment4inpatientswithcolorectallivermetastasesaretrospectivecohortstudy
AT haqhafizul segment23hypertrophyisgreaterwhenrightportalveinembolisationisextendedtosegment4inpatientswithcolorectallivermetastasesaretrospectivecohortstudy
AT luolorna segment23hypertrophyisgreaterwhenrightportalveinembolisationisextendedtosegment4inpatientswithcolorectallivermetastasesaretrospectivecohortstudy
AT wyattjudithi segment23hypertrophyisgreaterwhenrightportalveinembolisationisextendedtosegment4inpatientswithcolorectallivermetastasesaretrospectivecohortstudy
AT toogoodgilesj segment23hypertrophyisgreaterwhenrightportalveinembolisationisextendedtosegment4inpatientswithcolorectallivermetastasesaretrospectivecohortstudy
AT lodgejpetera segment23hypertrophyisgreaterwhenrightportalveinembolisationisextendedtosegment4inpatientswithcolorectallivermetastasesaretrospectivecohortstudy
AT pateljaiv segment23hypertrophyisgreaterwhenrightportalveinembolisationisextendedtosegment4inpatientswithcolorectallivermetastasesaretrospectivecohortstudy